Loading stock data…
GENB
$13.43+0.65 (+5.09%)
Market OpenUpdated 3:50 PM EDT
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$13.43
Potential Downside
0%
Whystock Fair Value$13.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.03%
Volume
Today's trading volume
516,781
Recent News
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains
Recent trading snapshot and business context Generate Biomedicines (GENB) has drawn investor interest after a mixed stretch in the stock, with a small gain of 0.2% over the past day set against a decline of 9.7% over the past week. Over the past month the stock is roughly flat, while the past 3 months show a gain of 10.0%. This recent trading context sits alongside a market value of about US$1.68b and a share price of US$13.12 at the last close. See our latest analysis for Generate...
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
A Deep Dive Into NVIDIA’s Latest Portfolio Moves
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the best low priced biotech stocks to invest in. On April 13, H.C. Wainwright initiated coverage of Generate Biomedicines, Inc. (NASDAQ:GENB) with a Buy rating, setting a $16 price target. The firm told investors in a research note that the stock has fallen over 20% even as GB-0895 advanced into […]
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness
Generate Biomedicines: Recent Trading Moves And Core Business Snapshot Generate Biomedicines (GENB) has seen recent share price pressure, with a 10% decline over the past week and a similar move over the past month, bringing the latest close to US$11.21. For context, the company reports revenue of US$31.893 million alongside a net loss of US$249.523 million, reflecting the costs of developing its generative biology platform and early stage pipeline of protein based therapeutics. See our...